GP方案化疗联合恩度治疗老年非小细胞肺癌的效果及对预后的影响研究

目的探究GP方案化疗联合恩度治疗老年非小细胞肺癌(NSCLC)的效果及对表皮生长因子受体(EGFR)与肿瘤异常蛋白(TAP)水平的影响。方法回顾性分析2015年1月至2017年1月的中晚期老年NSCLC病人76例,对照组使用GP化疗方案(吉西他滨+顺铂)(37例);观察组使用GP化疗联合恩度方案(39例)。比较2组病人化疗后的临床疗效、肿瘤进展情况,并比较化疗前后的卡氏行为状态评分(KPS)、生活质量评分(QOL)、血清EGFR和末梢血TAP阳性率以及不良反应发生情况。结果观察组疾病控制率(DCR)显著高于对照组(P<0. 05)。观察组中位生存时间显著高于对照组(P<0. 05)。治疗后观察组KPS、QOL评分均显著高于对照组(P<0. 05)。2组血清EGFR和末梢血TAP阳性率均显著低于对照组(P<0. 05)。2组间3～4级不良反应发生率差异无统计学意义(P>0. 05)。结论使用GP化疗方案联合恩度治疗中晚期老年NSCLC病人,具有更好的临床效果,值得临床推广。

Efficacy of GP chemotherapy combined with endostar on elderly patients with non-small cell lung cancer and effects on prognosis

Objective To explore the efficacy of GP-based chemotherapy combined with endonate in the treatment of non-small cell lung cancer(NSCLC)in the elderly patients and investigate the effects on the levels of epidermal growth factor receptor(EGFR)and tumor abnormal protein(TAP).Methods The clinical data of 76 elderly patients with advanced NSCLC from January 2015 to January 2017 were retrospectively analyzed.The patients were divided into two groups,the control group treated with GP chemotherapy(Gemcitabine+Cisplatin)(37 cases);the observation group treated with GP chemotherapy combined with endo regimen(39 cases).The clinical efficacy and tumor progression of the two groups after chemotherapy were compared.Karnofsky performance score(KPS),quality of life(QOL)score before and after chemotherapy,serum EGFR and peripheral blood TAP positive rates,and the incidence of adverse reactions were compared between the two groups.Results The disease control rate(DCR)in the observation group was significantly higher than that in the control group(P<0.05).The median survival time was significantly higher in the observation group than that in the control group(P<0.05).The KPS and QOL scores in the observation group after treatment were significantly higher than those in the control group(P<0.05).After treatment,the serum EGFR and peripheral blood TAP positive rate in the observation group were significantly lower than those in the control group(P<0.05).There was no significant difference in the incidence of grade 3 or 4 adverse reactions between the two groups(P>0.05).Conclusions GP chemotherapy combined with endor in the treatment of middle-aged and elderly patients with NSCLC has better clinical effect and more benefits,which is worthy of clinical promotion.